The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.
If you are a wholesale investor under the definition of that term in clause 3 of Part 1 Schedule 1 of the Financial Markets Conduct Act 2013, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.
You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.
Following good interest at Enterprise Angels’ November Pitch night, we to extend the invitation to invest in Advemto to the wider wholesale investment community. Understanding how biological cells work is crucial for life sciences. It's essential for developing new drugs and diagnosing diseases.
Fluorescent Labelling: This technique uses special glowing markers that attach to specific molecules in cells. These markers help scientists identify and study these molecules by capturing the light they emit.
The Problem: Current technology for analysing these fluorescent labels is not very effective. Only a few markers can be detected at once due to interference from the cell's natural glow. This makes the process slow and expensive - taking up to a year and costing up to $2 million per clinical trial.
Advemto’s Solution: Advemto’s innovative '2D Barcode Reader' is a breakthrough in this field. Developed over ten years, this tool uses advanced spectroscopy to turn blurry fluorescent signals into clear, distinct 2D barcodes. This means it can identify hundreds of biomarkers at once, making the process faster and cheaper.
Company Leadership:
- Prof. Justin Hodgkiss: CEO & CSO, founding inventor, award-winning research leader.
- Dr. Ronnie Tamming: Product Engineer, spectroscopy expert, formerly at Robinson Research Institute.
- Douglas Bock: Product Engineer, with industry experience from Fraunhofer (Germany).
- A team of advisors with diverse scientific and commercial expertise.
Revenue Model: Revenue will come from selling the Barcode Reader hardware, which can be used with existing customer equipment, and from subscriptions to Advemto’s software. The technology has various applications, including:
- Flow Cytometry: Initial target market with a total addressable market (TAM) of $2.5 billion.
- Microscopy, Bulk Analysis, Spatial Biology, Panel Design: Other applications of the technology.
Next Steps: Advemto is starting its first pilot trial at the Malaghan Institute. Feedback from these trials will guide further development. The company aims to secure initial adoption in 20-30 key opinion leader labs globally.
Commercial Success: Advemto has already successfully commercialised its MatriX-1 optical reader with $800k in pre-seed funding. The company is now raising seed funding, led by Movac, to further develop the 2D Barcode Reader and achieve market validation.
Value Realisation for Shareholders: NZGCP has kindly agreed to share their DD report with investors on a strictly non-reliance + confidential basis. Their modelled returns show a realistic pathway to a 22x return for shareholders. We encourage you to read the full report and conduct your own thorough due diligence.
AIP Registered Company: $1 invested counts as $3 towards the Active Investor Plus Visa conditions.
The Offer:
- Raising $2.5 million - $3.5 million
- $6m pre-money valuation
- Preference Shares
- Movac leading with $1.5 million
Further deal information available on registration of interest includes:
- Pitch Deck & Pitch Recording
- DD report
- DD Q&A recording
- Deal Memo
- Background Information
Note: This round is already well subscribed and may close at any time so act now if you are keen to invest. Minimum investment parcel is $5,000. You will be charged an admin fee upon investment, along with an exit fee on divestment. For more fee info please check here
